{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:22:46Z","timestamp":1772166166836,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eurasian Harm Reduction Network"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Programmatic and financial sustainability of health responses dependent on donor funding has risen as a major concern. In the HIV field in particular, it generated a number of instruments and assessments on sustainability and processes related to donor transition planning. The authors aimed to develop an instrument specific to opioid agonist therapy (OAT) programs as they were addressed only marginally by the HIV-specific assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The development of the OAT sustainability instrument used desk review of existing HIV sustainability concepts and tools, an International Advisory Board, and piloting to validate the instrument.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The new OAT sustainability instrument is comprised of the three parts: the conceptual framework, methodological guidelines and a practical implementation tool for assessing the degree of OAT sustainability at the country level. It measures sustainability in the three broad areas for sustainability measuring\u2013Policy &amp; Governance; Finance &amp; Resources; and Services. The selection of indicators and their composites for the three sustainability areas extensively used the United Nations and World Health Organization\u2019s guidance on health system building blocks, on care and HIV and viral hepatitis\u00a0prevention among people using opioids and for opioid dependence, and the definition of access to health framed by the United Nations Convent on Economic, Social and Cultural Rights. The instrument\u2019s methodological guidelines require the engagement of a national consultant to conduct desk review, key informant interviews and focus groups for measuring discrete milestones and adding qualitative information for interpretation of the data, progress and opportunities. The guidelines advise engaging a country-specific multi-stakeholder advisory group for planning, validation and follow-up of the assessment. The pilot of the instrument in 3 countries in 2020 validated it and required minor adjustments in the instrument. By mid-2023, the instrument has been successfully applied in 5 countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The developed instrument enables a comprehensive review of the resilience of OAT programs and their ability to scale up and to inform a roadmap for improved sustainability. While developed in the context\u00a0of Eastern Europe and Central Asia, it has been reviewed by a global advisory panel and could be easily adapted outside this regional context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-024-00931-0","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T22:02:11Z","timestamp":1705010531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund support"],"prefix":"10.1186","volume":"21","author":[{"given":"Raminta","family":"Stuikyte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Varentsov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergii","family":"Dvoriak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"1","key":"931_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1744-8603-9-57","volume":"9","author":"LR Hirschhorn","year":"2013","unstructured":"Hirschhorn LR, Talbot JR, Irwin AC, May MA, Dhavan N, Shady R, Ellner AL, Weintraub RL. From scaling up to sustainability in HIV: potential lessons for moving forward. Glob Health. 2013;9(1):1\u20139. https:\/\/doi.org\/10.1186\/1744-8603-9-57.","journal-title":"Glob Health"},{"issue":"1","key":"931_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2989\/16085906.2016.1138976","volume":"15","author":"G Oberth","year":"2016","unstructured":"Oberth G, Whiteside A. What does sustainability mean in the HIV and AIDS response? Afr J AIDS Res. 2016;15(1):35\u201343. https:\/\/doi.org\/10.2989\/16085906.2016.1138976.","journal-title":"Afr J AIDS Res"},{"key":"931_CR3","unstructured":"The Global Fund Sustainability, Transition and Co-financing Policy (Board decision GF\/B35\/04 \u2013 Revision 1, Decision Point 08). https:\/\/www.theglobalfund.org\/media\/4221\/bm35_04-sustainabilitytransitionandcofinancing_policy_en.pdf. Accessed 11 Oct 2023."},{"key":"931_CR4","unstructured":"Cook C, Davies Ch. The lost decade: Neglect for harm reduction funding and the health crisis among people who use drugs. Harm Reduction International, 2018."},{"key":"931_CR5","unstructured":"The Global Fund Strategy 2017\u20132022: Investing to End Epidemics. https:\/\/www.theglobalfund.org\/media\/2531\/core_globalfundstrategy2017-2022_strategy_en.pdf. Accessed 10 Aug 2023"},{"key":"931_CR6","unstructured":"Hecht R, Flanagan K, Huffstetler H, Yamey GM. Donor transitions from HIV programs: what is the impact on vulnerable populations?. Health Affairs Forefront. 2018."},{"key":"931_CR7","unstructured":"World Health Organization Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence, 2019."},{"key":"931_CR8","unstructured":"World Health Organization. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations, 2022."},{"issue":"2","key":"931_CR9","first-page":"258","volume":"7","author":"G Gotsadze","year":"2019","unstructured":"Gotsadze G, Chikovani I, Sulaberidze L, Gotsadze T, Goguadze K, Tavanxhi N. The challenges of transition from donor-funded programs: results from a theory-driven multi-country comparative case study of programs in Eastern Europe and Central Asia supported by the Global Fund. Global Health: Science and Practice. 2019;7(2):258\u201372.","journal-title":"Global Health: Science and Practice"},{"key":"931_CR10","unstructured":"Eurasian Harm Reduction Network. TRAT \u2013 Transition Readiness Assessment Tool: Assessing the Sustainability of Harm Reduction Services Through and Beyond the Transition Period from Global Fund Support to Domestic Funding. 2016."},{"key":"931_CR11","unstructured":"Serebryakova L, Cook C, Davies, Ch. Failure to Fund: The Continued Crisis for Harm Reduction Funding in Low- And Middle-Income Countries. Harm Reduction International, 2021."},{"issue":"2","key":"931_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.drugpo.2006.11.007","volume":"18","author":"A Sarang","year":"2007","unstructured":"Sarang A, Stuikyte R, Bykov R. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy. 2007;18(2):129\u201335. https:\/\/doi.org\/10.1016\/j.drugpo.2006.11.007.","journal-title":"Int J Drug Policy"},{"key":"931_CR13","unstructured":"Pates R, Riley D, editors. Harm reduction in substance use and high-risk behaviour. John Wiley & Sons; 2012 May 31."},{"key":"931_CR14","unstructured":"Stuikyte R. Perception of drugs in Central and Eastern Europe and Central Asia: overhaul needed. The Eastern and Central European and Central Asian Commission on Drug Policy (ECECACD), 2022. https:\/\/ececacd.org\/perception-of-drugs-in-central-and-eastern-europe-and-central-asia-overhaul-needed\/. Accessed 11 Oct 2023."},{"issue":"3","key":"931_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1749975509105538","volume":"3","author":"P Meylakhs","year":"2009","unstructured":"Meylakhs P. Drugs and symbolic pollution: the work of cultural logic in the Russian press. Cult Sociol. 2009;3(3):377\u201395.","journal-title":"Cult Sociol"},{"issue":"2","key":"931_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10461-022-03781-8","volume":"27","author":"S Lodi","year":"2023","unstructured":"Lodi S, Rossi SL, Bendiks S, Gnatienko N, Lloyd-Travaglini C, Vetrova M, Toussova O, Bushara N, Blokhina E, Krupitsky E, Ekstrand ML, Lioznov D, Samet JH, Lunze K. Correlates of intersectional HIV and substance use stigma affecting people with HIV and substance use in St. Petersburg, Russia. AIDS Behav. 2023;27(2):462\u201372. https:\/\/doi.org\/10.1007\/s10461-022-03781-8.","journal-title":"AIDS Behav."},{"issue":"6","key":"931_CR17","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1007\/s10461-022-03925-w","volume":"27","author":"J Owczarzak","year":"2023","unstructured":"Owczarzak J, Fuller S, Coyle C, Davey-Rothwell M, Kiriazova T, Tobin K. The relationship between intersectional drug use and HIV stigma and HIV care engagement among women living with HIV in Ukraine. AIDS Behav. 2023;27(6):1914\u201325. https:\/\/doi.org\/10.1007\/s10461-022-03925-w.","journal-title":"AIDS Behav"},{"issue":"68","key":"931_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drugpo.2019.02.007","volume":"1","author":"KL Stringer","year":"2019","unstructured":"Stringer KL, Mukherjee T, McCrimmon T, Terlikbayeva A, Primbetovac S, Darisheva M, Hunt T, Gilbert L, El-Bassel N. Attitudes towards people living with HIV and people who inject drugs: a mixed method study of stigmas within harm reduction programs in Kazakhstan. International Journal of Drug Policy. 2019;1(68):27\u201336. https:\/\/doi.org\/10.1016\/j.drugpo.2019.02.007.","journal-title":"International Journal of Drug Policy"},{"key":"931_CR19","unstructured":"Amaya AB, Gotsadze G, Chikovani I. The Road to Sustainability: Transition Preparedness Assessment Framework. Tbilisi: Curatio International Foundation. 2015."},{"key":"931_CR20","unstructured":"World Health Organization. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. 2010."},{"key":"931_CR21","unstructured":"WHO. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, 2009."},{"key":"931_CR22","unstructured":"WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users \u2014 2012 revision. Geneva; World Health Organization, 2012."},{"key":"931_CR23","volume-title":"diagnosis, treatment and care for key populations \u2014 2016 update","author":"WHO Consolidated guidelines on HIV prevention","year":"2016","unstructured":"WHO Consolidated guidelines on HIV prevention. diagnosis, treatment and care for key populations \u2014 2016 update. Geneva: WHO; 2016."},{"key":"931_CR24","unstructured":"WHO Access to hepatitis C testing and treatment for people who inject drugs and people in prisons a global perspective. Policy Brief. Geneva, WHO, April 2019."},{"key":"931_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-017-0141-6","volume":"14","author":"L Wiessing","year":"2017","unstructured":"Wiessing L, Ferri M, B\u011bl\u00e1\u010dkov\u00e1 V, Carrieri P, Friedman SR, Folch C, Dolan K, Galvin B, Vickerman P, Lazarus JV, Mrav\u010d\u00edk V. Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J. 2017;14:1\u20134. https:\/\/doi.org\/10.1186\/s12954-017-0141-6.","journal-title":"Harm Reduct J"},{"key":"931_CR26","unstructured":"United Nations Office on Drugs and Crime, International Network of People Who Use Drugs, Joint United Nations Programme on HIV\/AIDS, United Nations Development Programme, United Nations Population Fund, World Health Organization, United States Agency for International Development. Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions. Vienna: United Nations Office on Drugs and Crime; 2017."},{"key":"931_CR27","doi-asserted-by":"crossref","unstructured":"Mao W, McDade KK, Bharali I, Ogbuoji O, Yamey G. Transitioning from health aid: a scoping review of transition readiness assessment tools. The Center for Policy Impact in Global Health. Duke Global Working Paper Series: number 27, January 2021. https:\/\/centerforpolicyimpact.org\/our-work\/transitioning-from-health-aid-scoping-review-of-transition-readiness-assessment-tools\/. Accessed 10 Oct 2023.","DOI":"10.2139\/ssrn.3779348"},{"key":"931_CR28","unstructured":"Joint NGO Submission by the Promo-LEX Association,\u00a0Union for HIV Prevention and Harm Reduction (UORN)\u00a0and Eurasian Harm Reduction Association (EHRA) to UPR Working Group 40th\u00a0Session\u00a0United Nations Human Rights Council\u00a0Report: Issues Related to Drug Laws and Policies in Moldova and Their Impact on the Enjoyment of Human Rights. http:\/\/uorn.md\/joint-ngo-submission-upr-alternative-report-aspectele-ce-tin-de-legile-si-politicile-ce-vizeaza-consumul-de-droguri-in-republica-moldova-si-impactul-acestora-asupra-exercitarii-drepturilor-omului\/.Accessed 02 Feb 2023"}],"updated-by":[{"DOI":"10.1186\/s12954-024-00945-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000}}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00931-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T03:10:51Z","timestamp":1706670651000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00931-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00931-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3511464\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12954-024-00945-8","URL":"https:\/\/doi.org\/10.1186\/s12954-024-00945-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as the manuscript does not report on or involve the use of any animal or human data or tissue. The instrument described in the article requires getting consent to provide interviews or participate in focus groups.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}